Unlike those digital notebooks, which are appealing because they lack traditional displays, the XP-Pen Magic Note Pad uses a ...

Highlighting Marvell’s strong positioning in the AI sector, Arya pointed out how the company has secured a significant win with Amazon for the next-generation 3nm AI program, which is likely to ...

Two of these stocks trade for high valuations, but their potential for growth fueled by AI makes them worth the price. The other has a fast-growing AI business as part of a slower-growing ...

The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...

NEW YORK – The UK National Institute for Health and Care Excellence on Thursday issued two updated draft guidances recommending against making Eisai and Biogen's Leqembi (lecanemab) and Eli Lilly's ...

Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...

O n March 1st, engineer Zakwan Ahmad launched his concept for "The One Smart AI Pen" on Kickstarter, debuting a device that looks on a surface level like a standard ballpoint pen ...

"One Smart AI Pen", currently launched for crowdfunding on Kickstarter. | Credit: Zakwan Ahmad on Kickstarter On March 1st, engineer Zakwan Ahmad launched his concept for "The One Smart AI Pen" on ...

You may have seen the “Sell me that pen. It’s AI-powered” meme if you are a social media user. It may have started as a joke, but Zakwan Ahmad made the meme become reality with “The One Smart AI Pen” ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...